Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00731549
Registration number
NCT00731549
Ethics application status
Date submitted
5/08/2008
Date registered
11/08/2008
Date last updated
26/11/2014
Titles & IDs
Public title
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Query!
Scientific title
A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients With Schizophrenia
Query!
Secondary ID [1]
0
0
31-08-248
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ASPIRE
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Schizophrenia
0
0
Query!
Condition category
Condition code
Mental Health
0
0
0
0
Query!
Schizophrenia
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Aripiprazole IM Depot
Experimental: 1 - Active Treatment of aripiprazole IM depot (300mg or 400mg)
Treatment: Drugs: Aripiprazole IM Depot
300mg or 400mg
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Stable Participants at Baseline Who Remained Stable at Endpoint (Last Visit).
Query!
Assessment method [1]
0
0
"Stable" was defined as meeting all of the following criteria: Outpatient status; Positive and negative syndrome scale (PANSS) total score = 80; Lack of specific psychotic symptoms on the PANSS as measured by a score of = 4 on each of the following items (possible scores of 1 to 7 for each item): 1) conceptual disorganization 2) suspiciousness 3) hallucinatory behavior 4) unusual thought content; Clinical Global Impression of Severity (CGI-S) = 4 (moderately ill); and Clinical Global Impression for Severity of Suicidality (CGI-SS) = 2 (mildly suicidal) on Part 1 and = 5 (minimally worsened) on Part 2. The percentage of stable participants at baseline who remain stable at endpoint (last visit) is described here.
Query!
Timepoint [1]
0
0
Baseline to Week 52/Last visit
Query!
Secondary outcome [1]
0
0
Percentage of Participants Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria.
Query!
Assessment method [1]
0
0
"Impending relapse criteria" was defined as meeting all the following criteria: 1) Clinical Global Impression of Improvement (CGI-I) = 5 (minimally worse), AND an increase to score of >4 and absolute increase of = 2 on the individual PANSS items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content); or an increase to score >4 and absolute increase of = 4 on the combined 4 PANSS items on any of these PANSS items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content) OR 2) Hospitalization due to worsening of psychotic symptoms, but excluding hospitalization for psychosocial reasons, OR 3) CGI-SS score of 4 (severely suicidal) or 5 (attempted suicide) on Part 1 and/or 6 (much worse) or 7 (very much worse) on Part 2, OR 4) Violent behavior resulting in clinically relevant self-injury, injury to another person, or property damage.
Query!
Timepoint [1]
0
0
Weeks 2,4,8,12,16,20,24,28,32,36,40,44,48,52, and Last visit (upto 4 weeks ± 3 days after completion or withdrawal)
Query!
Secondary outcome [2]
0
0
Percentage of Participants Achieving Remission.
Query!
Assessment method [2]
0
0
Remission is defined as a score of = 3 on each of the following specific PANSS items, maintained for a period of six months: delusions, unusual thought content, hallucinatory behavior, conceptual disorganization, mannerisms/posturing, blunted affect, social withdrawal, and lack of spontaneity.
Query!
Timepoint [2]
0
0
Overall remission from Weeks 2,4,8,12,16,20,24,28,32,36,40,44,48 and 52
Query!
Secondary outcome [3]
0
0
Percentage of Participants Stable at Baseline and Remaining Stable at Week 28.
Query!
Assessment method [3]
0
0
"Stable" was defined as meeting all of the following criteria: Outpatient status; PANSS total score = 80; Lack of specific psychotic symptoms on the PANSS as measured by a score of = 4 on each of the following items (possible scores of 1 to 7 for each item): 1) conceptual disorganization 2) suspiciousness 3) hallucinatory behavior 4) unusual thought content; Clinical Global Impression of Severity (CGI-S) = 4 (moderately ill); and Clinical Global Impression for Severity of Suicidality (CGI-SS) = 2 (mildly suicidal) on Part 1 and = 5 (minimally worsened) on Part 2. The percentage of stable participants at baseline who remain stable at Week 28 is described here.
Query!
Timepoint [3]
0
0
Baseline to Week 28
Query!
Secondary outcome [4]
0
0
Percentage of Participants With Time to First Exacerbation of Psychotic Symptoms/Impending Relapse.
Query!
Assessment method [4]
0
0
Participants who first time meet relapse criteria were considered as having an event at date of exacerbation of psychotic symptoms/impending relapse. Time to first event was calculated as the earliest date of meeting one of relapse criteria. Limited concurrent treatment with oral aripiprazole was permitted as rescue therapy.
Query!
Timepoint [4]
0
0
Baseline to Week 52
Query!
Secondary outcome [5]
0
0
Mean Change From Baseline to Endpoint (Last Visit) in Positive and Negative Syndrome Scale (PANSS) Total Score.
Query!
Assessment method [5]
0
0
PANSS total score (range 30-210) is the sum of the rating scores for 7 positive scale items, 7 negative scale items and 16 general psychopathology scale items from the PANSS scale. PANSS positive subscale score (range 7-49) is the sum of the rating scores for the 7 positive scale items from the PANSS scale. PANSS negative subscale score (range 7-49) is the sum of the rating scores for the 7 negative scale items from the PANSS scale. The severity of each scale is rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms.
Query!
Timepoint [5]
0
0
Baseline, Weeks 12, 24, 52 and last visit
Query!
Secondary outcome [6]
0
0
Mean Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score.
Query!
Assessment method [6]
0
0
To assess CGI-S, the rater or physician will answer the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices include: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.
Query!
Timepoint [6]
0
0
Baseline, Weeks 12, 24, 52 and last visit
Query!
Secondary outcome [7]
0
0
Mean Change From Baseline to Endpoint in PANSS Positive and Negative Subscales.
Query!
Assessment method [7]
0
0
PANSS positive subscale score (range 7-49) is the sum of the rating scores for the 7 positive scale items from the PANSS scale. Positive subscale consists of 7 positive symptom constructs: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility). PANSS negative subscale score (range 7-49) is the sum of the rating scores for the 7 negative scale items from the PANSS scale. Negative subscale consists of 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive pathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking). The severity of each scale is rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms.
Query!
Timepoint [7]
0
0
Baseline, Weeks 12, 24, 52 and last visit
Query!
Secondary outcome [8]
0
0
Mean Clinical Global Impression of Improvement (CGI-I) Score.
Query!
Assessment method [8]
0
0
To assess CGI-I the rater or physician will rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses will be compared to the participants condition at baseline. Response choices include: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.
Query!
Timepoint [8]
0
0
Weeks 2, 4, 12, 24, 52 and last visit
Query!
Secondary outcome [9]
0
0
Percentage of Participants Who Discontinued Due to All Causes.
Query!
Assessment method [9]
0
0
Participants who discontinued due to any cause were noted. Limited concurrent treatment with oral aripiprazole was permitted as rescue therapy.
Query!
Timepoint [9]
0
0
Baseline to Week 52
Query!
Eligibility
Key inclusion criteria
- Subjects who are able to provide written informed consent and/or consent obtained from
a legally acceptable representative (as require by IRB/IEC), prior to the initiation
of any protocol-required procedures.
- Male and female subjects 18 to 65 years of age, inclusive, at time of informed
consent.
- Subjects who complete Studies 246/247 or who withdrew from the double-blind
maintenance phase of either study (Phase 4 of Study 246 or Phase 3 of Study 247), or
new subjects not participating in Studies 246/247.
- # Subjects who, in the investigator's judgment, require chronic treatment with an
antipsychotic medication.
- Subjects able to understand the nature of the study and follow protocol requirements,
including the prescribed dosage regimens, tablet ingestion, IM depot injection,
discontinuation of prohibited concomitant medications, who can read and understand the
written word in order to complete patient-reported outcomes measures, and who can be
reliably rated on assessment scales.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Subjects with a current DSM-IV-TR diagnosis other than schizophrenia, including
schizoaffective disorder, major depressive disorder, bipolar disorder, delirium,
dementia, amnestic or other cognitive disorders. Also, subjects with borderline,
paranoid, histrionic, schizotypal, schizoid or antisocial personality disorder.
- Subjects with schizophrenia that are considered resistant/refractory to antipsychotic
treatment by history or response only to clozapine.
- Subjects with a significant risk of violent behavior or a significant risk of
committing suicide based on history or investigator's judgment.
- Subjects who currently meet DSM-IV-TR criteria for substance dependence; including
alcohol and benzodiazepines, but excluding caffeine and nicotine, or two positive drug
screens for cocaine.
- Subjects who are known to be allergic, intolerant, or unresponsive to prior treatment
with aripiprazole or other quinolinones.
- Subjects with a history of hypersensitivity to antipsychotic agents.
- Subjects with a history of neuroleptic malignant syndrome or clinically significant
tardive dyskinesia at screening.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/12/2008
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/11/2013
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1081
Query!
Recruitment in Australia
Recruitment state(s)
VIC,WA
Query!
Recruitment hospital [1]
0
0
- Dandenong
Query!
Recruitment hospital [2]
0
0
- Epping
Query!
Recruitment hospital [3]
0
0
- Frankston
Query!
Recruitment hospital [4]
0
0
- Fremantle
Query!
Recruitment hospital [5]
0
0
- Glenside, SA
Query!
Recruitment hospital [6]
0
0
- Melbourne
Query!
Recruitment postcode(s) [1]
0
0
3175 - Dandenong
Query!
Recruitment postcode(s) [2]
0
0
3076 - Epping
Query!
Recruitment postcode(s) [3]
0
0
3199 - Frankston
Query!
Recruitment postcode(s) [4]
0
0
6959 - Fremantle
Query!
Recruitment postcode(s) [5]
0
0
5063 - Glenside, SA
Query!
Recruitment postcode(s) [6]
0
0
VIC 3004 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Connecticut
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
District of Columbia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Georgia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Illinois
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Indiana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Louisiana
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Maryland
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Mississippi
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Missouri
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Nebraska
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
New Mexico
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
New York
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
North Carolina
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Ohio
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Oklahoma
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Pennsylvania
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
South Carolina
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Tennessee
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Texas
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Virginia
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Washington
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Wisconsin
Query!
Country [27]
0
0
Argentina
Query!
State/province [27]
0
0
Buenos Aires
Query!
Country [28]
0
0
Argentina
Query!
State/province [28]
0
0
Cordoba, Cordoba
Query!
Country [29]
0
0
Argentina
Query!
State/province [29]
0
0
La Plata, Buenos Aires
Query!
Country [30]
0
0
Argentina
Query!
State/province [30]
0
0
Mendoza
Query!
Country [31]
0
0
Austria
Query!
State/province [31]
0
0
Innsbruck
Query!
Country [32]
0
0
Belgium
Query!
State/province [32]
0
0
Brugge
Query!
Country [33]
0
0
Bulgaria
Query!
State/province [33]
0
0
Bourgas
Query!
Country [34]
0
0
Bulgaria
Query!
State/province [34]
0
0
Lovech
Query!
Country [35]
0
0
Bulgaria
Query!
State/province [35]
0
0
Pazardjik
Query!
Country [36]
0
0
Bulgaria
Query!
State/province [36]
0
0
Pleven
Query!
Country [37]
0
0
Bulgaria
Query!
State/province [37]
0
0
Plovdiv
Query!
Country [38]
0
0
Bulgaria
Query!
State/province [38]
0
0
Radnevo
Query!
Country [39]
0
0
Bulgaria
Query!
State/province [39]
0
0
Rousse
Query!
Country [40]
0
0
Bulgaria
Query!
State/province [40]
0
0
Sofia
Query!
Country [41]
0
0
Bulgaria
Query!
State/province [41]
0
0
Varna
Query!
Country [42]
0
0
Bulgaria
Query!
State/province [42]
0
0
Veliko Tarnovo
Query!
Country [43]
0
0
Chile
Query!
State/province [43]
0
0
San Bernardo, Santiago
Query!
Country [44]
0
0
Chile
Query!
State/province [44]
0
0
Santiago
Query!
Country [45]
0
0
Croatia
Query!
State/province [45]
0
0
Zagreb
Query!
Country [46]
0
0
Estonia
Query!
State/province [46]
0
0
Jamejala
Query!
Country [47]
0
0
Estonia
Query!
State/province [47]
0
0
Tallinn
Query!
Country [48]
0
0
Estonia
Query!
State/province [48]
0
0
Tartu
Query!
Country [49]
0
0
Finland
Query!
State/province [49]
0
0
Helsinki
Query!
Country [50]
0
0
France
Query!
State/province [50]
0
0
Elancourt
Query!
Country [51]
0
0
France
Query!
State/province [51]
0
0
Rennes
Query!
Country [52]
0
0
France
Query!
State/province [52]
0
0
St. Nazaire
Query!
Country [53]
0
0
Hungary
Query!
State/province [53]
0
0
Baja
Query!
Country [54]
0
0
Hungary
Query!
State/province [54]
0
0
Balassagyarmat
Query!
Country [55]
0
0
Hungary
Query!
State/province [55]
0
0
Cegléd
Query!
Country [56]
0
0
Hungary
Query!
State/province [56]
0
0
Gyor
Query!
Country [57]
0
0
India
Query!
State/province [57]
0
0
Gujarat
Query!
Country [58]
0
0
India
Query!
State/province [58]
0
0
Karnataka
Query!
Country [59]
0
0
India
Query!
State/province [59]
0
0
Tamil Nadu
Query!
Country [60]
0
0
India
Query!
State/province [60]
0
0
Kanpur
Query!
Country [61]
0
0
India
Query!
State/province [61]
0
0
Mangalore
Query!
Country [62]
0
0
India
Query!
State/province [62]
0
0
Pune
Query!
Country [63]
0
0
India
Query!
State/province [63]
0
0
Tirupati
Query!
Country [64]
0
0
Korea, Republic of
Query!
State/province [64]
0
0
Busan
Query!
Country [65]
0
0
Korea, Republic of
Query!
State/province [65]
0
0
Deajeon
Query!
Country [66]
0
0
Korea, Republic of
Query!
State/province [66]
0
0
Gwangju
Query!
Country [67]
0
0
Korea, Republic of
Query!
State/province [67]
0
0
Joong-gu, Incheon
Query!
Country [68]
0
0
Korea, Republic of
Query!
State/province [68]
0
0
Seoul
Query!
Country [69]
0
0
Malaysia
Query!
State/province [69]
0
0
Perak
Query!
Country [70]
0
0
Malaysia
Query!
State/province [70]
0
0
Wilayah Persekutuan
Query!
Country [71]
0
0
Malaysia
Query!
State/province [71]
0
0
Selangor
Query!
Country [72]
0
0
Mexico
Query!
State/province [72]
0
0
DF
Query!
Country [73]
0
0
Mexico
Query!
State/province [73]
0
0
Jalisco
Query!
Country [74]
0
0
Mexico
Query!
State/province [74]
0
0
Nuevo León
Query!
Country [75]
0
0
Mexico
Query!
State/province [75]
0
0
Sinaloa
Query!
Country [76]
0
0
Mexico
Query!
State/province [76]
0
0
San Luis Potosí
Query!
Country [77]
0
0
Norway
Query!
State/province [77]
0
0
Aalesund
Query!
Country [78]
0
0
Norway
Query!
State/province [78]
0
0
Klepp stasjon
Query!
Country [79]
0
0
Philippines
Query!
State/province [79]
0
0
Central Luzon
Query!
Country [80]
0
0
Philippines
Query!
State/province [80]
0
0
NCR
Query!
Country [81]
0
0
Philippines
Query!
State/province [81]
0
0
Western Visayas
Query!
Country [82]
0
0
Poland
Query!
State/province [82]
0
0
Belchatow
Query!
Country [83]
0
0
Poland
Query!
State/province [83]
0
0
Bialystok
Query!
Country [84]
0
0
Poland
Query!
State/province [84]
0
0
Bydgoszcz
Query!
Country [85]
0
0
Poland
Query!
State/province [85]
0
0
Choroszcz
Query!
Country [86]
0
0
Poland
Query!
State/province [86]
0
0
Kraków
Query!
Country [87]
0
0
Poland
Query!
State/province [87]
0
0
Leszno
Query!
Country [88]
0
0
Poland
Query!
State/province [88]
0
0
Pruszkow
Query!
Country [89]
0
0
Poland
Query!
State/province [89]
0
0
Sosnowiec
Query!
Country [90]
0
0
Poland
Query!
State/province [90]
0
0
Wroclaw
Query!
Country [91]
0
0
Puerto Rico
Query!
State/province [91]
0
0
San Juan
Query!
Country [92]
0
0
Romania
Query!
State/province [92]
0
0
Arad
Query!
Country [93]
0
0
Romania
Query!
State/province [93]
0
0
Bucuresti
Query!
Country [94]
0
0
Romania
Query!
State/province [94]
0
0
Cluj-Napoca
Query!
Country [95]
0
0
Romania
Query!
State/province [95]
0
0
Craiova
Query!
Country [96]
0
0
Romania
Query!
State/province [96]
0
0
Oradea
Query!
Country [97]
0
0
Romania
Query!
State/province [97]
0
0
Pitesti
Query!
Country [98]
0
0
Russian Federation
Query!
State/province [98]
0
0
Lipetsk
Query!
Country [99]
0
0
Russian Federation
Query!
State/province [99]
0
0
Moscow
Query!
Country [100]
0
0
Russian Federation
Query!
State/province [100]
0
0
Nizhny Novgorod
Query!
Country [101]
0
0
Russian Federation
Query!
State/province [101]
0
0
Smolensk
Query!
Country [102]
0
0
Russian Federation
Query!
State/province [102]
0
0
St. Petersburg
Query!
Country [103]
0
0
Serbia
Query!
State/province [103]
0
0
Belgrade
Query!
Country [104]
0
0
Serbia
Query!
State/province [104]
0
0
Kragujevac
Query!
Country [105]
0
0
Slovakia
Query!
State/province [105]
0
0
Kosice
Query!
Country [106]
0
0
Slovakia
Query!
State/province [106]
0
0
Liptovsky Mikulas
Query!
Country [107]
0
0
Slovakia
Query!
State/province [107]
0
0
Presov
Query!
Country [108]
0
0
Slovakia
Query!
State/province [108]
0
0
Rimavska Sobota
Query!
Country [109]
0
0
Slovakia
Query!
State/province [109]
0
0
Svidnik
Query!
Country [110]
0
0
South Africa
Query!
State/province [110]
0
0
Gauteng
Query!
Country [111]
0
0
South Africa
Query!
State/province [111]
0
0
Western Province
Query!
Country [112]
0
0
Spain
Query!
State/province [112]
0
0
Barcelona
Query!
Country [113]
0
0
Taiwan
Query!
State/province [113]
0
0
Tainan
Query!
Country [114]
0
0
Taiwan
Query!
State/province [114]
0
0
Taipei
Query!
Country [115]
0
0
Thailand
Query!
State/province [115]
0
0
Chiangmai
Query!
Country [116]
0
0
Thailand
Query!
State/province [116]
0
0
Bangkok
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Otsuka Pharmaceutical Development & Commercialization, Inc.
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
Covance
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
To evaluate the overall effectiveness of aripiprazole intramuscular (IM) depot as maintenance
treatment in patients with schizophrenia.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00731549
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00731549
Download to PDF